

# APASL STC Nagasaki

## Poster Free Paper Sessions

17:00~18:30 on April 10 (Mon) 2017

### At Room 3 “ASUKA”, 1<sup>st</sup> Floor

#### <HBV>

**P-001. Transient Elastography is Useful for the Evaluation of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B Virus Infection Treated with Entecavir**

Masaaki Shimada (Japan)

**P-002. Antiplatelet Therapy is Associated with Better Prognosis in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma after Liver Resection**

Po-Chun Chen (Taiwan)

**P-003. Investigate the Relevant Factors Associated with Low-titer Hepatitis B Surface Antigen Carrier: A Community-based Study**

Cheng-Hung Chien (Taiwan)

**P-004. Influence of Hepatitis B Virus Genotypes on Innate Immune Response by Impairing Mitochondrial Antiviral Signaling Protein**

Kenichi Morikawa (Japan)

**P-005. Hepatitis B Virus X Protein Modulates Host Restriction Factor via Interaction with DDB1**

Takaaki Izumi (Japan)

**P-006. Fusion HBx from HBV Integrant might Alter ER Stress Response and Contribute to Hepatocarcinogenesis**

Ryosuke Muroyama (Japan)

**P-007. Association of Vitamin D-related Genetic Variations and Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B**

Umaporn Limothai (Thailand)

**P-008. The Value of Using HBsAg and HBcrAg in Combination for the Assessment of HCC Risk**

Yuichiro Suzuki (Japan)

**P-009. Activated  $\gamma$  &  $\delta$  T Cells Concomitantly Exhibit Cytotoxicity and the Capacity for Viral Clearance in Patients with Acute Hepatitis B**

Yuanyuan Li (China)

**P-010. MicroRNA 17-92 Induces Methylation of Hepatitis B Virus DNA in Human Hepatoma Cells**

In Young Moon (Korea)

**P-011. TRAIL Receptor 1 (TRAIL-R1) Polymorphisms are Associated with Risk of Hepatitis B Related Hepatocellular Carcinoma**

Apichaya Khlaiphuengsin (Thailand)

**P-012. The Characteristics and Outcomes of Patients Dropped out Nucleotide Analogs Therapy**  
Shuichi Matsumoto (Japan)

**P-013. A Case of Hepatocellular Carcinoma Developed during Administration of Entecavir for De Novo Hepatitis B Reactivation**

Yukiko Okamoto (Japan)

**P-014. Association of NTCP Polymorphisms with Clinical outcome of Hepatitis B Infection in a Thai Cohort**

Nongnaput Tuyapala (Thailand)

**P-015. Cross Sectional Assessment of Knowledge, Attitude and Practice (KAP) on Hepatitis B and Hepatitis C, Prevalence, and Risk Factors among High Risk Individuals**

Peter Andrew C. Reyes (Philippines)

**P-016. Variation in the PreS/S Gene in HBV-associated HCC Patients with the HLA-DPB1 0201 Allele**

Yumi Hakozaiki (Japan)

**P-017. Hepatitis B Core Related Antigen in Sera is the Surrogate Marker for HBV Covalently Closed Circular DNA Regardless Nucleic Acid Analogues Treatment**

Takeshi Matsui (Japan)

**P-018. Usefulness of ALBI Grade in Prediction of Outcomes in Patients with Hepatitis B Related Hepatocellular Carcinoma**

Kazuyuki Mizuno (Japan)

<HCV-Post SVR>

**P-019. Early Recurrence of HCC after Successful Treatment with DCV plus ASV**

Noboru Hirahima (Japan)

**P-020. Risk of Hepatocellular Carcinoma after Sustained Virologic Response by Interferon-free Treatment Compared with Interferon-based Treatment for Chronic Hepatitis C**

Naoto Kawabe (Japan)

**P-021. Efficacy and HCC Development after DAAs Therapy for Patients with Chronic Hepatitis C**

Akitoshi Douhara (Japan)

**P-022. Evaluation of Anti Carcinogenic Effect after Antiviral Therapy (PEG-IFN and DAA) for Type C Chronic Liver Disease Patients**

Koichi Takaguchi (Japan)

**P-023. Recurrence Pattern in Patients who underwent Antiviral Therapy after Curative Treatment of HCV Related Hepatocellular Carcinoma**

Yutaka Yasui (Japan)

**P-024. Development of Hepatocellular Carcinoma after Treatment with Direct Acting Antivirals in Hepatitis C Virus-related Chronic Liver Diseases**

Kyo Sasaki (Japan)

**P-025. Assessment with Characteristics and Risk of Developing Hepatocellular Carcinoma after Eradication of Hepatitis C Virus by Interferon-free Therapy**

Etsuko Iio (Japan)

**P-026. Two Cases of Rapid-growing Hepatocellular Carcinoma after Direct Acting Anti-viral Treatment of Hepatitis C Virus Infection**

Toshihiro Kawaguchi (Japan)

**P-027. The Preventive Effect for Recurrence by Interferon-free DAA Treatment in the Patients with HCC Curative Treatment**

Masakuni Tateyama (Japan)

**P-028. Development of Hepatocellular Carcinoma in the Patient Occurred Newly just after Sustained Virological Response to Ledipasvir/Sofosbuvir against Chronic Hepatitis C: a Case Report**

Daiki Ozono (Japan)

**P-029. The Features of Hepatocellular Carcinoma following Treatment with Direct-acting Antivirals for Hepatitis C**

Seiichi Mawatari (Japan)

**P-030. The Incidence of Hepatocellular Carcinoma after Daclatasvir plus Asunaprevir Therapy in HCV-1b Hepatitis who Achieved Sustained Virologic Response**

Mitsuaki Sato (Japan)

**P-031. Hepatocellular Carcinoma Occured after Exclusion of Hepatitis C Virus with Interferon-free Treatment**

Hideo Kunimoto (Japan)

**P-032. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment**

Ming-Lung Yu (Taiwan)

**P-033. A Case of Diffuse Hepatocellular Carcinoma Diagnosed after DAA Treatment**

Takeaki Satoh (Japan)

**P-034. Characteristics and Prognosis of Patients with Hepatocellular Carcinoma that Developed after Hepatitis-C Virus Eradication**

Tatsuya Minami (Japan)

**P-035. Analysis of Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir for Hepatitis C Virus Infection**

Hiroshi Ida (Japan)

<HCV>

**P-036. Analysis of the Relationship between Alcohol Drinking and HCV-related Hepatocellular Carcinoma by Estimation of Lifetime Total Alcohol Intake**

Masanori Tokoro (Japan)

**P-037. Comparison of the Anti-HCV Effects of IFN-based Therapy and IFN-free Therapy for Patients after Curative HCC Treatment**

Akihiro Tamori (Japan)

**P-038. Diversity of the Association of Serum Levels and Genetic Variants of MHC Class I Polypeptide-related Chain A with Liver Fibrosis in Chronic Hepatitis C**

Jee-Fu Huang (Taiwan)

**P-039. Effectiveness of Sofosbuvir-based Regimens for Japanese Patients with HCV Genotype 1 or 2 Infection: Real Life Experience from a Multicenter Cohort**

Eiichi Ogawa (Japan)

**P-040. Polymorphisms in MICA, but not in DEPDC5, HCP5 or PNPLA3, are Associated with Chronic Hepatitis C-Related Hepatocellular Carcinoma**

Hoang Hai (Japan)

**P-041. Liver Dysfunction Caused by Daclatasvir and Asunaprevir Combination Therapy-its Influence on the SVR Rate and the Association with the Drug-metabolizing Enzyme Polymorphisms**

Natsuhiko Kuratomi (Japan)

**P-042. Gene Expression Profile on Hepatocellular Carcinoma Cells with Different Intracellular Hepatitis C Viral Load**

Chia-Yen Dai (Taiwan)

**P-043. Hepatitis C Virus Infection: A Case Series**

Angelo Jonathan D. Cruz (Philippines)

**P-044. HCV Management in Mongolia**

Naranzul Nyamsuren (Mongolia)

**P-045. Ledipasvir and Sofosbuvir Treatment Results for Hepatitis C Genotype 1b Patients in Mongolia**

Baatarkhuu O (Mongolia)

**P-046. The Efficacy of Peginterferon plus Ribavirin in Patients with Genotype 1 Chronic Hepatitis C in Mongolia**

Uugantsetseg G (Mongolia)

<NAFLD>

**P-047. Impact of Vitamin D Replacement on Liver Enzymes in Non-Alcoholic Fatty Liver Disease Patients**

Suparuedee Boonyagard (Thailand)

**P-048. Combination Treatment of Dipeptidyl Peptidase IV Inhibitor (Sitagliptin) and Angiotensin-II Type 1 Receptor Blocker (Losartan) Suppresses Progression in a Nondiabetic Rat Model of Steatohepatitis**

Shinya Sato (Japan)

**P-049. The Role of PPAR $\beta$ / $\delta$  in CD11b+ Resident Liver Macrophages on Liver Steatosis**

Jiapeng K. Chen (Singapore)

**P-050. Characteristics of Elderly Patients with Nonalcoholic Fatty Liver Disease**

Maki Tobaru (Japan)

**P-051. The Association between Serum Levels of Sptlc3 and the Clinical Features of Patients with NAFLD**

Sho Ijyuin (Japan)

At Room 4 “PEARL”, 12<sup>th</sup> Floor

<HCC-Basic>

P-052. **Anti-tumor Effect of Carnosic Acid on Human Hepatoma Cell Lines**

Ting Wang (Japan)

P-053. **Antitumoral Effect of SGLT2 Inhibitor against Human Liver Cancer**

Kosuke Kaji (Japan)

P-054. **Dual Therapy with Acyclic Retinoid and Angiotensin-II Receptor1 Blocker Ameliorates Chemically Induced Hepatocarcinogenesis in Diabetic OLETF Rats**

Norihisa Nishimura (Japan)

P-055. **Angiotensin II Receptor Blocker Attenuates Human Cholangiocarcinoma through Inhibition of the Hippo-YAP Signaling Pathway**

Soichiro Saikawa (Japan)

P-056. **Preventive Effects of the Sodium Glucose Cotransporter 2 Inhibitor Tofogliflozin on Liver Tumorigenesis in Obese Mice**

Yohei Shirakami (Japan)

P-057. **DPP-4 Inhibitor Suppresses the Progression of Hepatocellular Carcinoma through Activation of Chemotaxis of NK Cells in Mice**

Sohji Nishina (Japan)

P-058. **The Epigenetic Roles of Protein Kinase R in Hepatocellular Carcinoma with Hepatitis C Virus Infection, and Possibility of PKR Inhibitor as a Therapeutic Target**

Takao Watanabe (Japan)

P-059. **Down-regulated Expression of ANP32B has Anti-apoptotic Function in Hepatocellular Carcinoma**

Yoshinori Ohno (Japan)

P-060. **The Role of Heme Oxygenase-1 in Liver Cancer Development and Progression**

Xiaowen Mao (Hong Kong)

P-061. **Systems Approach to Characterize the Metabolism of Liver Cancer Stem Cells Expressing CD133**

Seung Kew Yoon (Korea)

P-062. **ELK3 Promotes the Migration and Invasion of Liver Cancer Stem Cells by Targeting HIF-1 $\alpha$**

Seung Kew Yoon (Korea)

P-063. **Histone Deacetylase-targeted Exploration for Expression Inducer of MHC Class I Polypeptide-related Sequence A**

Sayaka Ito (Japan)

P-064. **Iron Chelator Suppresses Hepatocarcinogenesis through Mitophagy Induction in STAM Mice**

Yuichi Hara (Japan)

P-065. **Rapid Progression of Hepatocellular Carcinoma in Neuropeptide Y Knockout Mice**

Ayaka Kinoshita (Japan)

**P-066. Hepatoprotective Effect of Isotoma longiflora (L) Presl. Leaves Extract on Carbon Tetrachloride-induced Hepatotoxicity in Mice**

Enikarmila Asni (Indonesia)

**P-067. Glycolysis Inhibitors Enhance Inhibition of Hepatoma Cell Growth**

Jae Hee Choi (Korea)

**P-068. Effect of the Anti-diabetic Drug Metformin in Hepatocellular Carcinoma in Vitro and in Vivo**

Asahiro Morishita (Japan)

**P-069. Screening, Identification Antivascular Biomarkers of Hepatocellular Carcinoma**

Kun Yan (China)

### <HCC-Clinical>

**P-070. Transarterial Infusion of Epirubicin and Cisplatin Combined with Systemic Infusion of 5-fluorouracil Versus Transcatheter Arterial Chemoembolization Using Doxorubicin for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis**

Sung Won Lee (Korea)

**P-071. Does Obesity with Visceral Fat Influence Recurrence and Survival in Patients with Hepatocellular Carcinoma?**

Atsushi Hiraoka (Japan)

**P-072. Comparison between Percutaneous Radiofrequency Therapy and Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: Early Experience of CyberKnife, SBRT System, in Our Hospital**

Yasuhide Motoyoshi (Japan)

**P-073. Long-term Survival Result of Patients with Hepatocellular Carcinoma Treated with Trans-arterial Chemoembolization Using Drug-loaded Microspheres**

Thai Doan Ky (Vietnam)

**P-074. Efficacy of Sorafenib for Hepatocellular Carcinoma and Impact on Prognosis**

Taketo Nishina (Japan)

**P-075. Treatment of Hepatocellular Carcinoma by Radiofrequency Ablation Using Cool-tip RF Electrode: Prospective Results on 82 Patients**

Nguyen Thi Thu Huyen (Vietnam)

**P-076. Factors Associated with the Prognosis of Patients with Non-hepatitis B Virus-, Non-hepatitis C Virus-related Hepatocellular Carcinoma**

Yu Noda (Japan)

**P-077. Non-hypervascular Hepatobiliary Phase Hypointense Nodules on Gd-EOB-DTPA-enhanced MRI as a Risk Factor for Intrahepatic Distant Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation**

Masanori Inoue (Japan)

**P-078. Analysis of Factors for Respiratory Depression and Severe Body Movement in Radiofrequency Ablation under Deep Sedation**

Koki Sato (Japan)

**P-079. The Change of Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein (M2BPGi) is A Predictive Marker of the Recurrence of Hepatocellular Carcinoma in Patients after RFA**

Masato Nakai (Japan)

**P-080. Survival Outcome of Resectable HCC in Young Adult: A Single Center Experience**

Sunhawit Junrungsee (Japan)

**P-081. Clinicopathological Characteristics of Non-B Non-C Hepatocellular Carcinoma without Past HBV Infection**

Takefumi Kimura (Japan)

**P-082. Hepatectomy is Beneficial to Intermediate and Advanced Hepatocellular Carcinoma: A Cohort Study in Taiwan**

Chi-Ling Chen (Taiwan)

**P-083. Sarcopenia as Prognostic Factor in Hepatocellular Carcinoma**

Benjamin T Castro Jr (China)

**P-084. Three Cases Report of the Sorafenib Treatment for Hepatocellular Carcinoma who are Advanced age, about an Effect and Tolerability**

Yasunari Kaneyama (Japan)

**P-085. Survival Benefit of Liver Resection for Hepatocellular Carcinoma with Hepatic Vascular Invasion**

Yasuhiro Nakayama (Japan)

**P-086. Decreased EGFL6 Expression is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma**

Hui Ting Hsu (Taiwan)

**P-087. Prognostic Role of Circulating miR-221 in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization**

Piyawan Chailapakul (Thailand)

**P-088. Natural History of Untreated Hepatocellular Carcinoma in Thai Patients: A Single-Center Experience**

Siwaporn Chainuvati (Thailand)

**P-089. Effectiveness of Drug-eluting Bead-transarterial Chemo-embolization in Intermediate Stage of Hepatocellular Carcinoma**

Akihiro Deguchi (Japan)

**P-090. Pure Laparoscopic Right Hepatectomy for HCC with Umbilical Zigzag Incision**

Toshio Shikano (Japan)

**P-092. Conversion Therapy with Hepatic Arterial Infusion Chemotherapy for Long-term Prognosis in Patients with Advanced Hepatocellular Carcinoma Involving Vascular Invasion**

Hiroaki Nagamatsu (Japan)

**P-093. Epidemiology, Clinical Features and Prognosis of Hepatocellular Carcinoma in Mongolia: A Multi-center Study**

Baatarkhuu O (Mongolia)

<LC>

P-094. This paper has been withdrawn

**P-095. The Relationship between Malnutrition Universal Screen Tool (MUST) Scores and Liver Function Indexes in Cirrhotic Patients**

Ying-Chen Hung (Taiwan)

**P-096. Effect of Raloxifene on Rats with Biliary Cirrhosis**

Ching-Chih Chang (Taiwan)

**P-097. The Mortality of Cirrhotic Patients with Heart Failure**

Yen-Chun Chen (Taiwan)

**P-098. Food Consumption Behavior in Elderly Cirrhotic Patients**

Fang-Yen Kuo (Taiwan)

**P-099. A Patient with Liver Cirrhosis Confirmed Reduction in Activity of Lysosomal Acid Lipase (LAL)**

Yuki Kugiyama (Japan)

**P-100. Efficacy of Tolvaptan for Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma**

Motonori Shimizu (Japan)

**P-101. Hepatopulmonary Syndrome is Closely Related with Bacterial Translocation in Cirrhosis**

Moon Young Kim (Korea)

**P-102. Adverse Outcomes after Non-hepatic Surgery in Patients with Liver Cirrhosis: A Nationwide Study**

Chien-Chang Liao (Taiwan)

**P-103. N Butyl 2 Cyanoacrylate Therapy of Bleeding Gastric Fundal Varices: The Experience of Tertiary Care Hospitals**

Farhan Haleem (Pakistan)

**P-104. The Role of Partial Splenic Artery Embolization in Cirrhotic Patients with Hypersplenism**

Ayman N. Menessy (Egypt)

**P-105. Difference of Thrombocytopenia between Alcoholic and Viral LC**

Seulki Kim (Korea)

**P-106. Fontan-associated Liver Disease: Diagnosis by Elastography and Laparoscopic Liver Biopsy**

Yohei Koizumi (Japan)

**P-107. The Significance of the Assessment of Liver Stiffness at Medical Health Checkup**

Taro Shibuki (Japan)

**P-108. Comparative Study of Non-invasive Liver Fibrosis Assessment Methods between Patients with and without Hepatocellular Carcinoma**

Akemi Tsutsui (Japan)

<Others>



**P-109. IgG4 Sclerosing Cholangitis and Post Infantile Giant Cell Hepatitis: A Case Report of an Extraordinary Copresentation**

Maha Elabaawy (Egypt)

**P-110. Case Report: A Case of Acute Liver Failure in A 52-year Old Female Caused by Autoimmune Hepatitis (AIH) Masquerading as Non-alcoholic Fatty Liver Disease (NAFLD)**

Chuck Eduard B. Galon (Philippines)

**P-111. Utilization of Computerized Database System to Facilitate the Efficiency of Case Management for the Chronic Hepatitis B and Hepatitis C Patients in Liver Clinic**

I Ling Liu (Taiwan)

**P-112. Epidemiological Study on Age-sex Stratified Prevalence of HBV, HCV and HAV in 1200 Random Samples from General Population and Employees**

Chikako Yamamoto (Japan)

**P-113. Fasciola Liver Abscess: An Unrecognized and Fatal but Curable Disease**

Siripa Puasripun (Thailand)

**P-114. Mixed Pyogenic and Tuberculous Liver Abscess in 67 Year Old Female**

Francis Rodencio B. Mantilla (Philippines)

**P-115. Comparing Response Rate between High Dose and Standard Dose Hepatitis B Vaccination in Cirrhotic Patients**

Petcharee Polmanee (Thailand)

**P-116. Post-transplant Diabetes Mellitus after Liver Transplantation: Risk Factors for Persistence**

Yang Won Nah (Korea)

**P-117. The Effect of Acute Pancreatitis on the Mortality of Patients with Liver Cirrhosis**

Tsung Hsing Hung (Taiwan)

**P-118. The Close Linkage between the Elasticity Modulus Measured by 2D Shear Wave Elastography and the Presence of Hepatocellular Carcinoma in Patients with a SVR to Interferon for CH-C**

Yasuharu Imai (Japan)

**P-119. Interventional Oncology (IVO) Suite at Juntendo University, New RFA Treatment Room**

Masashi Takawa (Japan)